Skip to main content

Table 4 RMST ratio between low- and high-risk groups based on immune risk score or immune clinical score in training, validation dataset-1 and validation dataset-2

From: An individualized immune prognostic signature in lung adenocarcinoma

RMST (years) Immune risk score Immune clinical score
Low risk (95% CI) High risk (95% CI) Ratio (95% CI) Low risk (95% CI) High risk (95% CI) Ratio (95% CI)
Training dataset 8.01 (7.62–8.40) 5.45 (4.91–5.99) 1.47 (1.32–1.64) 8.66 (8.27–9.04) 5.55 (5.09–6.02) 1.56 (1.42–1.71)
Validation dataset-1 6.34 (5.87–6.83) 5.05 (4.49–5.62) 1.26 (1.10–1.44) 6.46 (6.06–6.87) 3.25 (2.56–3.93) 1.99 (1.60–2.48)
Validation dataset-2 3.29 (3.13–3.45) 2.85 (2.59–3.11) 1.16 (1.04–1.28) 3.36 (3.22–3.51) 2.60 (2.32–2.90) 1.29 (1.15–1.46)
  1. CI confidence interval, RMST restricted mean survival time